Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
Status:
Completed
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
The hypothesis is that the SGLT-2 inhibitor empagliflozin reduces tissue sodium content in
patients with chronic heart failure, and if the hypothesis is proven, that this mechanism
contributes to the beneficial effects found in EMPA-REG Outcome trial potentially via
exerting beneficial effects on the vascular structure and function of the micro- and
macrocirculation.